Array, BMS partner to evaluate binimetinib plus Opdivo, Yervoy in mCRC

Array BioPharma Inc. (NASDAQ:ARRY) and Bristol-Myers Squibb Co. (NYSE:BMY) partnered to evaluate Array’s binimetinib (MEK162) in combination with PD-1 inhibitor Opdivo nivolumab with or without Yervoy ipilimumab to treat metastatic colorectal cancer (mCRC) in patients with microsatellite stable tumors.

Next half, the partners plan to start a Phase I/II trial to determine the recommended dose regimens and evaluate safety, tolerability and preliminary antitumor activity of the combinations...